Introduction
It has been reported that oral squamous cell carcinoma (OSCC) is the commonest oral malignancy, with ~300,000 new cases worldwide annually. 1 Although tremendous progress has been achieved in radical surgery combined with postoperative radiotherapy/chemoradiotherapy, patient 5-year survival rate has not improved essentially in recent decades. Therefore, early detection, early diagnosis, and early treatment are very important to increase the 5-year survival rate of patients with OSCC. Novel and specific biomarkers are required to solve this problem.
Molecular changes are regarded as potential biomarkers for cancers. In OSCC, some genes have been reported as potential biomarkers, such as KPNA2, HOXA13, HOXD13, EZH2, and LEF1. [2] [3] [4] [5] They had certain value in the diagnosis, treatment, and prognosis of OSCC, but it was not enough to obtain sensitivity and specificity for OSCC only by them. CLIC1 is a member of the highly conserved category of chloride-channel proteins that exists in both integral membrane and soluble forms. 6 It is abundant in the apical domains of epithelia. 7 Recently, CLIC1 has been reported to be responsible for regulating the However, whether CLIC1 plays an important role in tumorigenesis and progression of OSCC remains elusive.
To determine the role of CLIC1 in OSCC, we examined CLIC1 mRNA and protein expression in OSCC tissues and plasma. Moreover, we analyzed the association between CLIC1 expression and clinicopathological characteristic in OSCC. In addition, we elucidated the prognostic role of CLIC1 in OSCC patients. Finally, we found that CLIC1 was associated with multiple tumor-associated genes.
Methods sample preparation and clinicopathological data
An immunohistochemistry analysis was conducted on OSCC specimens collected from 72 patients who had undergone radical surgical resection (without prior radiotherapy or chemotherapy) from January 2012 to February 2013 at the Research Center of Pathology, Chongqing Medical University. A total of 26 pairs freshly frozen OSCC and corresponding noncancerous tissue samples were used for quantitative real-time (qRT) PCR and Western blot; 76 plasma samples included 54 OSCC plasma samples collected from OSCC patients and 22 healthy controls. All tissue and blood samples were collected at the Stomatological Hospital of Chongqing Medical University, China from 2017 to 2018 and used for qRT-PCR, Western blotting, and ELISA analysis. This study was approved by the Ethics Committee of the Stomatological Hospital of Chongqing Medical University, and all patients provided informed written consent before enrollment. Collection and processing of tissue and blood samples were conducted in accordance with the Declaration of Helsinki.
All tissue samples and blood samples were collected from patients and stored using the standard procedure. 25 These samples had undergone only one freeze-thaw cycle before the study was carried out. Telephone interviews were conducted routinely for at least 6 months during follow-up. Time from diagnosis to death or last follow-up visit was regarded as survival time and was checked at the last telephone interview in February of 2018, regardless of whether the patient was alive or not.
immunohistochemistry
Standard immunoperoxidase staining was used for immunohistochemical staining and CLIC1 protein expression in normal and malignant samples evaluated. Each section was semiquantitatively scored based on the extent and intensity of immunoreactivity: 0, 10% immunoreactive cells; 1, #25% immunoreactive cells; 2, 25%-75% immunoreactive cells; and 3, .75% immunoreactive cells. Additionally, staining intensity was graded on a 0-3 scale: 0, negative; 1, weak; 2, intermediate; and 3, strong. The final score was designated as the sum of extent and intensity and samples categorized as negative (0), weak (1-2), moderate (3), and strong staining (4) (5) (6) . For statistical calculations, moderate and strong staining 
real-time quantitative Pcr
Total RNA was isolated from tissue using Trizol reagent (Takara, Kusatsu, Japan). The primers used in this study were shown in Table 2 . RNA was reverse-transcribed into cDNA with a ReverTra Ace qRT-PCR kit (Takara, Japan). qRT PCR was performed on a StepOnePlus RT-PCR system (Thermo Fisher Scientific, Waltham, MA, USA). The reaction comprised an initial denaturation step of 95°C for 30 minutes, followed by 39 cycles of 95°C for 5 seconds, 60°C for 34 seconds, and a final extension step of 95°C for 10 minutes. The mRNA-expression level of the target gene in each sample was normalized to the GADPH control.
elisa
Blood samples in heparin tubes were centrifuged (2,000 g) at 4°C for 10 minutes to obtain plasma and frozen at -80°C for further analysis. CLIC1 protein levels in plasma were measured with human ELISA kits according to the manufacturer's instructions. The results were processed with an automated analyzer (PerkinElmer Inc., Waltham, MA, USA).
statistical analysis
Data were analyzed using SPSS 20.0. All data are expressed as means ± SD. Independent Student's t-tests and χ 2 tests were used to assess the effects of CLIC1 on tissue and plasma. The Kaplan-Meier test was used for univariate survival analysis. The Cox proportional-hazard model was used for multivariate analysis and for determining 95% CIs. Pearson correlation coefficients were used to assess correlations among tumor-associated genes. Results were regarded as significant at P,0.05.
Results

CLIC1 significantly upregulated in OSCC tissue
To evaluate CLIC1-expression status in human OSCC tissue, 26 pairs of OSCC and noncancerous oral tissue were collected to examine CLIC1 mRNA expression by qRT-PCR. Results showed that CLIC1 mRNA expression was upregulated in OSCC tissue (2.31±1.27) compared with noncancerous oral tissue (0.34±0.32, P=0.003; Figure 1C ). CLIC1 protein expression was higher in OSCC tissue (1.16±0.44) than paired noncancerous oral tissue (0.41±0.93) via Western blot, and this was consistent with qRT-PCR results. Furthermore, CLIC1 protein expression in different histological grades showed significant differences (P,0.001; Figure 1D and E).
clic1 expression associated with clinicopathological features in Oscc patients
To elucidate the biological functions of CLIC1 in OSCC development, the expression of this protein in OSCC was Figure 1B ). In addition, there were significant CLIC1 proteins of histological grade. Then, we evaluated correlations between CLIC1 expression and histopathological parameters in the OSCC patients. 
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clic1 as a potential biomarker for Oscc CLIC1-positive patients was obviously lower than that of patients with CLIC1-negative expression (P=0.025; Table 4 , Figure 2 ). To identify risk factors of prognosis precisely, univariate Cox regression analysis was used. These data revealed that CLIC1 expression, histological grade, and lymph-node metastasis were adversely correlated with postoperative survival time, suggesting that overexpression of CLIC1 is a risk factor for OSCC (Table 5 ).
Determination of clic1 as a plasma Oscc biomarker
As CLIC1 was overexpressed in OSCC tissues, we speculated that CLIC1 could be detected in blood samples of OSCC patients. To determine this possibility, a sensitive ELISA was conducted to detect the expression of CLIC1 protein in plasma. Plasma samples of 30 OSCC patients without any treatment, 14 who had undergone resection only, ten who 
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Xu et al had undergone resection and chemotherapy, and 22 healthy controls were examined. CLIC1 protein expression was significantly higher in OSCC plasma than that of healthy controls (P=0.023), CLIC1 protein expression obviously lower in resection patients than those of OSCC patients (P=0.039), and CLIC1-expression levels in resection-+ chemotherapytreated patients aberrantly lower than in resection-only patients and healthy controls (P=0.002 and P=0.000, respectively; Figure 3A) . Moreover, CLIC1-expression level in OSCC patients' plasma was also obviously higher in stage I-II than III-IV (P=0.002; Figure 3B ). However, there was no statistical difference between moderate differentiation and good differentiation (P=0.459; Figure 3C ).
correlation of CLIC1 and tumor-associated gene expression in Oscc tissue
In order for profound understanding of CLIC1, tumorassociated genes were detected. In OSCC tissue, CLIC1 mRNA-expression level of was positively correlated with PA28B, MMP2, MMP9, MMP13, and MMP12 mRNAexpression levels, whereas CLIC1 mRNA expression level was negatively correlated with ANXA7, GSN, and SERPINB5 mRNA-expression levels ( Figure 4) . Correlations between mRNA expression of GSN, PA28B, MMP2, MMP9, and MMP13 were significantly different from those of CLIC1 (P=0.043 and P,0.001).
Discussion
In this research, our results suggested that CLIC1 plays an important role in the tumorigenic potential of human OSCC. CLIC1 mRNA and protein were overexpressed in OSCC tissue and CLIC1 protein closely associated with patients' overall survival. Investigation indicated that CLIC1 is an independent metastasis and prognostic factor in OSCC. Moreover, CLIC1 protein was highly expressed in OSCC plasma and associated with therapy. Furthermore, our data demonstrated that CLIC1 may be involved in the pathway of development and metastasis of OSCC. Therefore, we consider CLIC1 has potential as a novel molecular therapeutic target and a possible outcome predictor. CLIC1 has been reported to be upregulated in human malignant tumors of the colon, brain, liver, stomach, and lung. 14, 22, 24, 26, 27 It was evaluated to be the most penetrating receptor among commonly dysregulated proteins within three sarcomas. 23 This protein plays an important role in the metastasis of colonic cancer. 24 In gliomas, CLIC1 expression is inversely related to patient survival. 27 Moreover, CLIC1 participates in regulation of aggression in human lung adenocarcinoma. 26 Consistently with upregulated CLIC1 expression in a large number of tumors, our data suggested that CLIC1 mRNA and protein were highly expressed in OSCC tissue. Firstly, our study discovered that CLIC1 exists mainly in the nucleus, cytoplasm, and cell membranes of OSCC patients. Next, this research found that increased CLIC1 protein 
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clic1 as a potential biomarker for Oscc expression was relevant not only to tumor progression but also to poor patient survival, indicating its materiality in OSCC advancement. Notably, Cox multivariate analysis suggested that CLIC1-overexpression level was an independent prognostic factor for OSCC patients. Therefore, CLIC1 is a potential molecular therapeutic target for OSCC.
Increasing attention has been paid to blood research. CLIC1 has also been detected in the blood of patients, suggesting that 
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Xu et al CLIC1 could be useful as a blood marker. CLIC1 proteins secrete from tumor cells and can enter the circulation. 28 Chang et al first reported that there exists the possibility of CLIC1 as a plasma marker for nasopharyngeal carcinoma.
8 CLIC1 has been confirmed to be overexpressed in ovarian cancer patient serum. 22 It seems to have recently become a popular view that CLIC1 may be applied as general cancer screening markers. We detected CLIC1 protein in plasma samples of OSCC patients, and found that its expression level was significantly higher than in normal controls. CLIC1 protein expression in plasma was also correlated with advanced tumor status. Furthermore, it was closely associated with treatment. These results indicated that CLIC1 expression could be regarded as a biomarker and in indices for tumor metastasis and prognosis in OSCC. However, CLIC1 needs to be evaluated with further testing of larger patient cohorts to avoid false positives or false negatives before clinical application. In addition, because CLIC1 is associated with histological grade, TNM, and tumor size, but not with lymph-node metastasis, it may require coordination with other biomarkers for diagnosis and treatment of OSCC. CLIC1 could be included in a group of select biomarkers for early detection.
Although the potential role of CLIC1 in cancer is not clear, there are have been many advances. Some studies have reported that CLIC1 is linked to many tumor-associated proteins. Wei et al found that downregulation of CLIC1 increased maspin expression and reduced MMP2, MMP9, MMP12, and VEGF expression. Conversely, upregulation of CLIC1 decreased maspin expression and increased MMP2, MMP12, VEGF, and MMP13 expression. 29 Zhang et al provided the novel insight that CLIC1 has a vital role in hepatocarcinoma metastasis, perhaps via regulation of gelsolin and annexin A7 expression. 30 Other research reported that knockdown of PA28B increased tumor invasion and migration through upregulation of CLIC1. 31 What is more, CLIC1 may be correlated with the regulation of integrin-family proteins, which leads to subsequent regulation of the PI3K-AKT, MAPK-p38, and MAPK-ERK pathways.
14 To evaluate the biological function of CLIC1 in OSCC pathogenesis further, we compared CLIC1 with tumor-associated genes using PCR. We found that CLIC1 was relevant to a variety of tumor genes, especially PA28B, MMP2, and MMP13, whereas PA28B and matrix metalloproteinases (MMPs) played an important role in tumor metastasis and invasiveness. 31, 32 These data indicated that CLIC1 may be involved in the pathway of development and metastasis of OSCC. In vitro experiments and experiments on animals are required to elucidate the mechanism of CLIC1 acting in OSCC.
Conclusion
In summary, this study detected the expression of CLIC1 in OSCC tissue and plasma. The results pointed to CLIC1 perhaps being a novel biomarker for OSCC diagnosis, prognosis, and even early screening. The potential use of CLIC1 as an OSCC biomarker needs to be evaluated with further testing of larger patient cohorts and in-depth mechanical experiments.
